Study personnel diverted to other activities and the study was not commenced

The primary objective of this research is to monitor chronic rhinosinusitis (CRS) symptoms in asthma patients who are undergoing treatment with reslizumab. A secondary objective is to explore whether there are sub-populations that appear to benefit or not benefit from reslizumab in terms of their CRS symptoms.

This is a prospective observational study of patients receiving reslizumab to treat their asthma. Some asthma patients receiving reslizumab also have CRS, which might also be improved by this drug. Study measures will be obtained from the medical records of eligible subjects who consent to participate. The study has no specific procedures per se, because all study measures are acquired during the course of standard of care treatment and will be abstracted from those medical records.

Inclusion Criteria:

• Age is 18 years or older
• Physician diagnosis of poorly controlled moderate to severe asthma despite typical medical therapy with an eosinophilic phenotype (defined by blood eosinophil count of 150 µL or greater within 6 weeks of enrollment)
• Initiating or undergoing reslizumab therapy (Reslizumab - Patient Information listed in Appendix 1 for reference)
• Physician diagnosis of chronic rhinosinusitis with nasal polyposis
• Able to understand and willing to provide informed consent
• Able to complete standard of care English-language questionnaires

Exclusion Criteria:

• Current smokers
• Significant uncontrolled medical conditions
• Ongoing malignancy or history of cancer in remission for less than 12 months
• Subjects who had received immunosuppressive medications within 3 months of enrollment

Patients with poorly controlled moderate to severe asthma with eosinophilia and a diagnosis of chronic rhinosinusitis with nasal polyposis